Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-8500a–midazolam pharmacokinetic interaction in healthy Japanese subjects
jRCT2080222622Phase 1
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of firuglipel in type 2 diabetes mellitus (T2DM), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Effect of DS-8500a on midazolam pharmacokinetics.
02
Drugs
firuglipel
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080222622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222622.